SS Innovations International (NASDAQ: SSII) has reported substantial growth in the adoption of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of September 8, 2026, a 79% increase from 7,885 at the end of 2025. The installed base of systems grew 42% to 238 units from 168, according to the company's recent update. This expansion underscores the increasing global demand for affordable robotic surgery and the company's progress in penetrating new markets.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been used for more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's ability to adapt its technology to diverse healthcare environments and address unmet medical needs.
SS Innovations also emphasized its achievements in pediatric and telesurgery. As of August 31, the company reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India. Such milestones illustrate the system's reliability and efficiency, which are critical for widespread adoption.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by year-end 2026. These regulatory approvals are pivotal for entering major markets and competing with established players. The full report is available at https://ibn.fm/DJILj.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the proprietary SSi Mantra system and the comprehensive suite of SSi Mudra surgical instruments, which support a variety of procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective solutions. For terms of use and disclaimers, visit https://IBN.ai/Disclaimer. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially. These statements are based on information available as of the date hereof, and the company undertakes no duty to update them unless required by law.
